V920 Vaccine

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus

Conditions

Ebola Virus

Trial Timeline

Dec 5, 2014 → Jun 23, 2016

About V920 Vaccine

V920 Vaccine is a phase 1 stage product being developed by Merck for Ebola Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT02314923. Target conditions include Ebola Virus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02314923Phase 1Completed

Competing Products

20 competing products in Ebola Virus

See all competitors